Breast cancer is one of the most common malignant tumors in women, and its incidence rate is increasing year by year. In Europe and the United States, breast cancer accounts for 25-30% of all malignant tumors in women. In China, with the improvement of people’s living standard, accelerated urbanization and change of lifestyle, the incidence of breast cancer has ranked first and second in some big cities. The number of incidence in rural areas is also increasing rapidly. The incidence of breast cancer in China has the following characteristics: 1) the age of onset is 10 years younger than that in the West; 2) the number of hormone receptor positive is lower than that in the West; 3) due to the imbalance of medical resources, the stage of diagnosis is later. In contrast, breast cancer is a highly heterogeneous group of malignant tumors with great differences in histomorphology, immunophenotype, biological behavior and therapeutic effects. With the application of molecular pathology and gene microarray technology, the expression profile of certain genes is gradually found to be closely related to the clinical signs of breast cancer, thus providing a scientific basis for molecular typing and individualized treatment of breast cancer. ”Triple-negative” breast cancer refers to breast cancer that is negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor. These breast cancers are highly homogenous, poorly differentiated, and have many similarities to BRCA1-associated breast cancers, which may originate from basal cells. They have a poor clinical prognosis and are prone to local recurrence and distant metastases. There is a lack of targeted and standardized treatment guidelines for this particular type of breast cancer. Clinical studies should be strengthened: 1. Molecular pathological features not only show ER, PR and HER-2 negativity, but also are often accompanied by high expression of HER-1, C-kit and P-cadherin and P5s, often with BRCA1 gene mutation. 2. Current status of treatment Currently, in clinical practice, there are five major treatments for breast cancer, surgery chemotherapy, radiotherapy, endocrine therapy and targeted therapy. Since the hormone receptor test is negative (ER, PR), clinical endocrine therapy is not effective for this type of tumor, while HER-2 expression is negative. Therefore, chemotherapy is a more mature treatment for this type of tumor, and anthracyclines and paclitaxel drugs used in clinical practice are all options. Although many chemotherapeutic agents are sensitive and effective, the genetic instability of TNBC can cause many potential mechanisms of drug resistance. Therefore, the combination or sequential administration of chemotherapy is mostly used, which can achieve a high response rate, but the overall clinical prognosis is still poor and progresses even after multi-drug use. Although HER-2 gene test is negative, expressing EGFR (HER-1) or stem cell factor receptor (C-kit), etc., so there are many attempts to give. New targeted drugs, such as Ebenezer, Bevacizumab, Gefitinib, Erlotinib, Imatinib, Lapatinib, etc., but the results are mostly poor. A new oral multikinase inhibitor, Dasatinib, has been shown in preliminary trials to inhibit the proliferative and metastatic properties of tumor cells and to be more sensitive to triple-negative breast cancer cells. In conclusion, due to the unique clinicopathological and molecular characteristics of these tumors and the poor prognosis of patients, they require more attention and continuous in-depth research.